MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • VolitionRx Ltd. (VNRX) Transforms Cancer Diagnostic And Screening Tests 0 comments
    Jan 17, 2014 2:38 PM | about stocks: VNRX

    VolitionRx, an ambitious life sciences company, wants to make non-invasive blood tests for cancer as commonplace and easy to use as current blood tests for diabetes and high cholesterol.

    With only one blood test for cancer-the Prostate-Specific Antigen test for prostate cancer-in common clinical use, VolitionRx reasoned that existing cancer diagnostic tests were inadequate. To address the unmet need in its field for accurate, inexpensive cancer diagnostics with potential for economic growth, the company began developing its NuQ brand of blood-based cancer diagnostic tests using its proprietary Nucleosomics technology which measures and identifies nucleosome structures in the blood. The presence of these structures in the bloodstream is a warning that cancerous cells are also present.

    VolitionRx is undergoing clinical trials for its NuQ products. Once these clinical trials are complete and regulatory approval is received, the company will offer blood tests for individual cancers under the NuQ brand. The company currently sells its NuQ immunoassays products to the research community and has plans to release a range of simple blood tests that will continue to expand with both screening and diagnostic cancer tests.

    VolitionRx is also in the midst of developing HyperGenomics, a new technology that aims to detect specific signatures from cancer biopsies by reading hypersensitive sites along the DNA string. These tests are being designed so that they can be used once cancer has been diagnosed to correctly identify the specific subtype of the disease and to help decide the most suitable therapy. Choosing the right treatment approach can significantly improve the treatment outcome, reduce side effects and deliver cost savings to paying patients.

    VolitionRx's research and development activities are centered in Belgium at the time as the company is focused on commercializing its diagnostic products first in Europe, then in the US and ultimately, around the world.

    For more information, visit volitionrx.com

    Stocks: VNRX
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.